Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CVL006 + pemetrexed + carboplatin
- Development stage
- Unknown
- Lead developer
- Convalife Pharmaceutical
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
CVL006 + pemetrexed + carboplatin is an investigational combination regimen studied in phase I/II clinical trials for advanced solid tumors, including non-small cell lung cancer, malignant pleural mesothelioma, and other cancers. CVL006 is an experimental agent evaluated for its safety, tolerability, pharmacokinetics, and preliminary efficacy in combination with standard chemotherapeutics pemetrexed and carboplatin. Pemetrexed is a folate antimetabolite, and carboplatin is a platinum-based alkylating agent; both disrupt cell division and DNA replication in tumor cells. The mechanism and molecular target of CVL006 are not publicly disclosed as of the current data. This multi-drug regimen is administered intravenously and aims to enhance the anti-tumor effects beyond standard chemotherapy[3][1][5][6].
- Other names
- pemetrexed + carboplatin
02
Targets
GART (GAR transformylase)TS (Thymidylate synthase)VEGFA (Vascular endothelial growth factor A)DHFR (Dihydrofolate reductase)CD274 (Programmed cell death protein 1 ligand 1)DNAATIC (Aminoimidazole carboxamide ribonucleotide transformylase)
Beyond the preview
Go deeper on CVL006 + pemetrexed + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CVL006 + pemetrexed + carboplatin.